Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. (Q54580043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Olivier Mir

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

4

Romain Coriat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Michel Tod

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Natacha Bancelin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Audrey Thomas-Schoemann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Fabrice Taieb

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Pascaline Boudou-Rouquette

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Stanislas Ropert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Judith Michels

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Halim Abbas

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Jean Philippe Durand

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alain Dauphin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Francois Goldwasser

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Benoit Blanchet

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

21 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

3199-3207

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Toxicity of sorafenib: clinical and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

The role of the protein-binding on the mode of drug action as well the interactions with other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composition: results of a novel ultrafiltration method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0499-1

In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albumin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21691893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21691893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11095-011-0499-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21691893%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference